Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Cure8 research brief
Why This Matters
For people with ulcerative colitis who have already tried and failed one or more advanced therapies, this study suggests upadacitinib may lead to higher rates of steroid-free clinical remission and endoscopic healing than tofacitinib or ustekinumab at 16 and 52 weeks.
Who Should Pay Attention
Patients with ulcerative colitis who are bio-experienced, clinicians choosing second-line advanced therapies, and researchers studying treatment sequencing in IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This abstract reports a retrospective multicenter study comparing three advanced therapies (upadacitinib, tofacitinib, ustekinumab) in patients with ulcerative colitis who had previously failed ≥1 advanced therapy.
The study evaluated steroid-free clinical remission and endoscopic remission at weeks 16 and 52 and used propensity-score inverse probability weighting to adjust comparisons.
Upadacitinib was associated with higher odds of steroid-free clinical remission and higher endoscopic remission rates at both 16 and 52 weeks compared with tofacitinib and ustekinumab in this bio-experienced UC cohort.
These results come from an observational, retrospective analysis rather than a randomized trial; that affects how confidently we can infer causality or apply results to an individual patient.
If you’re considering changing therapies after prior biologic or JAK failure, discuss these findings with your gastroenterologist to interpret them alongside your history, safety considerations, and local treatment availability.
Keep In Mind
This is a retrospective multicenter cohort (observational) reported as an abstract; it used statistical weighting to reduce confounding but is not a randomized head-to-head trial. Decisions about treatment should consider individual safety profiles, prior responses, and guideline recommendations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
AuthorsJoana Camões Neves, Dalila Costa, Margarida Cristiano +22 more
InstitutionGastroenterology Department, Unidade Local de Saúde Braga, Braga, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal. Electronic address: joanacamoesneves@gmail.com.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 6, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Sequential Biologic, Small-Molecule, and GLP-1 Analogue Therapy in Postcolectomy Enteritis With High Output Stoma.
People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.
The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease.
The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...